BeiGene (NASDAQ:BGNE) Upgraded to "Buy" at Zacks Investment Research
BeiGene (NASDAQ:BGNE – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $179.00 price objective on the stock. Zacks Investment Research‘s price objective points to a potential upside of 7.49% […]